Erin Boh, MD
Dermatology · New Orleans, LANPI 1790797454
Payments from drug & device makers
Across 490 payments — averaging $1928.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$203K
- AbbVie$161K
- Incyte Corporation$139K
- Eli Lilly$100K
- Johnson & Johnson$72K
- Janssen Research & Development, LLC$57K
- plus $213K from 25 others
What the payments were for
- Consulting fees$65,04423%
- Speaking & faculty fees$197,45471%
- Travel & lodging$6,6072%
- Food & beverage$8,0613%
- Education$2380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 87 | $203,253 |
| AbbVie | 62 | $160,537 |
| Incyte Corporation | 66 | $139,486 |
| Eli Lilly | 8 | $100,429 |
| Johnson & Johnson | 55 | $72,306 |
| Janssen Research & Development, LLC | 17 | $56,503 |
| E.r. Squibb & Sons, L.L.C. | 31 | $41,001 |
| Janssen Scientific Affairs, LLC | 27 | $37,619 |
| UCB, Inc. | 16 | $25,560 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 26 | $25,218 |
| Boehringer Ingelheim | 9 | $19,199 |
| Novartis | 9 | $15,185 |
| LEO Pharma Inc. | 8 | $8,482 |
| Boehringer Ingelheim International GmbH | 13 | $8,243 |
| Sanofi | 12 | $7,718 |
| Arcutis Biotherapeutics, Inc. | 7 | $7,015 |
| Vanda Pharmaceuticals Inc. | 2 | $6,000 |
| Sun Pharmaceutical Industries Inc. | 4 | $3,258 |
| Dermavant Sciences, Inc. | 5 | $3,244 |
| Bristol Myers Squibb | 2 | $1,767 |
| Bausch Health US, LLC | 2 | $1,306 |
| Lilly USA, LLC | 3 | $1,191 |
| Genentech USA, Inc. | 4 | $129 |
| Regeneron Healthcare Solutions, Inc. | 2 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Helsinn Therapeutics (U.S.), Inc. | 4 | $70 |
| Amgen | 3 | $63 |
| Stemline Therapeutics Inc. | 1 | $56 |
| Kerecis Limited | 2 | $53 |
| Revance Therapeutics, Inc. | 1 | $49 |
| Galderma Laboratories, L.p. | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$945,152 in reported general payments places this provider in the 95th percentile of 189 dermatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bexarotene | 179 | $1,197,487 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 72 | $962,668 |
| TargretinBexarotene | 17 | $514,143 |
| OtezlaApremilast | 94 | $483,886 |
| TremfyaGuselkumab | 34 | $475,461 |
| Skyrizi PenRisankizumab-Rzaa | 20 | $424,382 |
| Humira(Cf) PenAdalimumab | 59 | $422,673 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $289,460 |
| Cosentyx Unoready PenSecukinumab | 18 | $275,108 |
| Dupixent SyringeDupilumab | 66 | $246,425 |
| ValchlorMechlorethamine Hcl | 38 | $230,178 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $200,552 |
| Humira(Cf)Adalimumab | 25 | $179,962 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $175,694 |
| Cosentyx Sensoready PenSecukinumab | 11 | $164,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Octagam, Xeljanz | $203,253 | $1,192,82198 claims |
| Johnson & JohnsonTremfya, Remicade | $72,306 | $599,83654 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCTargretin | $25,218 | $514,14317 claims |
| AmgenOtezla | $63 | $483,88694 claims |
| AbbVieHumira(Cf), Rinvoq | $160,537 | $265,11338 claims |
| UCB, Inc.Cimzia (2 Pack) | $25,560 | $175,69415 claims |
| Incyte CorporationOpzelura | $139,486 | $75,03337 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $7,015 | $21,59325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 dermatology providers in Louisiana.
Other dermatology in New Orleans
- Deirdre HooperNew Orleans$3.2M
- Sarah JacksonNew Orleans$1.7M
- William ClaiborneNew Orleans$384K
- Mara HaseltineNew Orleans$276K
- Julie MermilliodNew Orleans$222K
- Patricia HickhamNew Orleans$12K
- Stephen KlingerNew Orleans$11K
- Jordan WhatleyBaton Rouge$27.9M
- Ira ThorlaBaton Rouge$5.6M
- Kyle ColemanThibodaux$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.